TGA / PMDA / NMPA · Asia-Pacific
intervention — TGA / PMDA / NMPA regulatory status
intervention regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 56 published clinical programs and 9 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| Brief motivational intervention | Phase 3 | BRIGHT MINDS BIOSCIENCES | NCT01419899 |
| Drug use prevention intervention | Phase 3 | BRIGHT MINDS BIOSCIENCES | NCT00310258 |
| Educational Intervention | Phase 3 | United Therapeutics Europe | NCT07186192 |
| HEPARIN , NADROPARIN | Phase 3 | Disc Medicine | 2023-509675-16-01 |
| Intervention | Phase 3 | Chinese Academy of | NCT01108614 |
| Intervention - a validated home BP monitor and support from the specialist nurse | Phase 3 | United Therapeutics Europe | NCT00514800 |
| Peer Mentoring Intervention for HCV-Infected IDUs | Phase 3 | BRIGHT MINDS BIOSCIENCES | NCT00391482 |
| Standard Brief Intervention | Phase 3 | BRIGHT MINDS BIOSCIENCES | NCT00876941 |
| Standard Care Intervention (SCI) | Phase 3 | BRIGHT MINDS BIOSCIENCES | NCT00503230 |
| behavior intervention and male circumcision | Phase 3 | Chinese Academy of | NCT01068015 |
| Brief computer-delivered intervention | Phase 2 | BRIGHT MINDS BIOSCIENCES | NCT00230048 |
| Brief motivational intervention | Phase 2 | BRIGHT MINDS BIOSCIENCES | NCT01124591 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 10874748 | Intervention for tendinopathy | US |
| 10525106 | Angiopoietin-based interventions for treating cerebral malaria | US |
| 10251938 | Angiopoietin-based interventions for treating cerebral malaria | US |
| 9968653 | Angiopoietin-based interventions for treating cerebral malaria | US |
| 9639665 | Methods for diagnosis and intervention of hepatic disorders | US |
| 9592271 | Angiopoietin-based interventions for treating cerebral malaria | US |
| 9457070 | Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease | US |
| 8613904 | Methods for diagnosis and intervention of hepatic disorders | US |
| 8403844 | Methods for interventions | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of intervention?
intervention currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get intervention regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to intervention?
This spoke lists 56 published programs associated with intervention in our pipeline index.